SecBot SecBot
SECBOTREPLAY Home › Report › GPCR

GPCR · Q3 net loss $144.8M, cash $1.2B

Structure Therapeutics Inc. · PRESS-RELEASE filed Nov 9, 2026 at 16:05 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed Nov 9, 2026 at 16:05 ET

Structure Therapeutics reported Q3 2026 net loss of $144.8M, wider than the $65.7M loss in Q3 2025, driven by increased R&D spending as the Phase 3 ACCOMPLISH program for aleniglipron initiates. Cash burn was $60M sequentially, leaving $1.2B in cash expected to fund operations through 2028. Key catalysts include aleniglipron supplementary data in Q4 2026 and ACCG-2671 MAD data in 1H 2027.

  • Net loss of $144.8M in Q3 2026 vs $65.7M in Q3 2025
  • Cash, cash equivalents and short-term investments of $1.2B as of Sep 30, 2026, down from $1.3B at Jun 30, 2026
  • Phase 3 ACCOMPLISH program for aleniglipron initiated in August 2026; topline data expected in 2H 2028
  • R&D expenses $134.6M in Q3 2026 vs $59.0M in Q3 2025

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access